[CONSOLIDATION_METHOD_TITLE] [CONSOLIDATION_METHOD]
Related Companies
[]
Related Funds
[]
English
oda_NewBusinessRelationAbstract|
New Business Relation
oda_UpdateAnnouncementFlag|
Update Notification Flag
Hayır (No)
oda_CorrectionAnnouncementFlag|
Correction Notification Flag
Hayır (No)
oda_DateOfThePreviousNotificationAboutTheSameSubject|
Date Of The Previous Notification About The Same Subject
-
oda_DelayedAnnouncementFlag|
Postponed Notification Flag
Hayır (No)
oda_AnnouncementContentSection|
Announcement Content
oda_NatureOfTheOtherPartyWithWhichNewBusinessRelationWillStart|
Nature Of The Other Party With Which New Business Relation Will Start
Tedarikçi (Supplier)
oda_NameSurnameOrCompanyTitleOfCustomerOrSupplier|
Name Surname Or Company Title Of Customer Or Supplier
Pfizer PFE İlaçları Anonim Şirketi
oda_IfExistsShareOfCustomerOrSupplierInNetSalesOrCostOfGoodsSoldOnLatestDisclosedProfitOrLossAndOtherComprehensiveIncomeStatementOfCompany|
If Exists Share Of Customer Or Supplier In Net Sales Or Cost Of Goods Sold On Latest Disclosed Profit Or Loss And Other Comprehensive Income Statement Of Company
0
oda_IfExistsShareOfCustomerOrSupplierInTradeReceivablesOrDebtsOnLatestDisclosedStatementofFinancialPositionOfCompany|
If Exists Share Of Customer Or Supplier In Trade Receivables Or Debts On Latest Disclosed Statement of Financial Position Of Company
0
oda_ExpectedStartingDateOfNewBusinessRelation|
Expected Starting Date O fNew Business Relation
01/05/2026
oda_IfExistSignificantProvisionsOfTheContractTextBlock|
If Exist Significant Provisions Of The Contract
Summarized below.
oda_ImpactOfNewBusinessRelationOnCompanyActivities|
Impact Of New Business Relation On Company Activities
Positive impact is expected.
oda_ExplanationSection|
Explanations
oda_ExplanationTextBlock|

-Unofficial Translation-

A Promotion, Sales, Distribution and Marketing Authorization Transfer Agreement has been signed between the two companies, effective for a period of 5 (five) years starting on May 1, 2026, for the purpose of Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. (GEN) exclusively conducting business operations and transactions in Türkiye, related to the sales, marketing, promotion and distribution of the products listed below, for which Pfizer PFE İlaçları Anonim Şirketi is the marketing authorization holder.

ELELYSO® 200 U Lyophilized Powder for IV Infusion Solution: It is used in the treatment of Gaucher Disease, a rare, genetic, and hereditary metabolic disorder characterized by the accumulation of certain fatty substances (lipids) in organs such as the spleen, liver, and bone marrow due to their inability to be broken down.

BESPONSA 1 mg Powder for Concentrate for the Preparation of Infusion Solution: It is used in the treatment of patients diagnosed with Precursor B-cell Acute Lymphoblastic Leukemia (ALL)—an aggressive type of blood cancer caused by the uncontrolled and rapid proliferation of lymphoblasts (the precursors of white blood cells known as lymphocytes) in the bone marrow—who are Philadelphia chromosome-negative and demonstrate CD22 positivity as confirmed by histopathological or flow cytometric analysis.

In case of any discrepancy between the Turkish and English texts, the Turkish text shall prevail.